Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Rhea-AI Summary
Palisade Bio (Nasdaq: PALI) will present virtually at the Needham & Co. 25th Annual Healthcare Conference April 14–17, 2026. The company presentation by CEO JD Finley and President & Chief Medical Officer Dr. Mitchell Jones is scheduled for April 16, 2026, 2:15–2:55 PM ET in Track 3.
A live webcast will be available on the Events page of the Investors section at palisadebio.com, with a replay archived for a limited time. Management will be available for one-on-one meetings with qualified, registered investors.
Positive
- None.
Negative
- None.
News Market Reaction – PALI
In the Apr 8 session, PALI declined 2.09%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Clinical trial data | Positive | -1.7% | Reported positive Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease. |
| Mar 02 | Investor conferences | Neutral | +2.3% | Announced participation in TD Cowen and Leerink investor conferences in March 2026. |
| Feb 23 | Clinical data update | Positive | +0.6% | Presented ECCO 2026 data showing colon‑targeted activity and encouraging safety for PALI-2108. |
| Feb 17 | Advisory appointment | Positive | -1.7% | Appointed IBD precision medicine expert to Clinical Advisory Board, outlining Phase 2 IND plans. |
| Feb 09 | Conference participation | Neutral | +4.9% | Announced virtual fireside chat at Piper Sandler immunology symposium with webcast and meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: positive clinical and advisory updates sometimes saw negative next-day moves, while neutral conference participation has occasionally aligned with modest gains.
Over the last few months, Palisade Bio has highlighted progress around PALI-2108 and investor outreach. On Mar 30, 2026, positive Phase 1b data in fibrostenotic Crohn’s disease showed a 47.5% SES-CD reduction and 40% endoscopic response/remission, yet shares fell 1.69%. Earlier, ECCO 2026 translational data on Feb 23 and a Clinical Advisory Board appointment on Feb 17 also focused on advancing PALI-2108. Multiple conference participations (TD Cowen, Leerink, Piper Sandler) underline ongoing investor-engagement efforts similar to today’s Needham appearance.
Key Terms
pde4 inhibitor medical
prodrugs medical
terminal ileum medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET
Access the webcast here
Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Needham & Co. 25th Annual Healthcare Conference, being held in a virtual format April 14–17, 2026.
The Company’s virtual presentation is scheduled for Thursday, April 16, 2026, from 2:15 PM to 2:55 PM ET in Track 3. A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered for the conference.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug.
Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
